comparemela.com
Home
Live Updates
Dr Mayer on the Use of CDK4/6 Inhibitors in HR+/HER2– Breast Cancer : comparemela.com
Dr Mayer on the Use of CDK4/6 Inhibitors in HR+/HER2– Breast Cancer
Erica L. Mayer, MD, MPH, discusses findings from research investigating CDK4/6 inhibitors in patients with hormone receptor (HR)–positive, HER2-negative breast cancer.
Related Keywords
Erical Mayer ,
,
Breast Cancer Clinical Research ,
Dana Farber Cancer Institute ,
Harvard Medical School ,
D ,
Bph ,
Dana Farber And Brigham Womens Hospital ,
Cdk4 6 Inhibitors ,
Patients With Hormone Receptor Positive ,
Her2 Negative Breast Cancer ,
comparemela.com © 2020. All Rights Reserved.